Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-heptyl–4-hydroxyquinoline N–oxide (HQNO) is a small molecule antibiotic produced by Pseudomonas aeruginosa and some Streptomyces species. It acts as an inhibitor of the mitochondrial respiratory chain at cytochrome bc1 and also inhibits photosynthetic electron flow before cytochrome b559. HQNO exhibits antibacterial activity, particularly against Staphylococcus aureus and other Gram-positive bacteria, and is implicated in microbial competition within environments such as the lungs of cystic fibrosis patients colonized by P. aeruginosa[1][7]. It is not approved for clinical use but has been studied experimentally for its antimicrobial properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-heptyl-4-hydroxyquinoline N-oxide.